Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.51 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.51 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | OTC | P00480 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | TGM2 | P21980 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20445992 | 1.00 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL10507212 | 1.00 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL20446016 | 1.00 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL20446014 | 0.98 | DDAH1 (0.50) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463086 | 0.95 | DDAH1 (0.56) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463087 | 0.95 | DDAH1 (0.56) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463174 | 0.87 | ALDH1A1 (0.45) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL19463173 | 0.87 | ALDH1A1 (0.45) | ZDHHC20ZDHHC2DDAH1GSROTC | |
| SCHEMBL20446015 | 0.85 | TGM2 (0.50) | ZDHHC20ZDHHC2DDAH1GSRTGM2 | |
| SCHEMBL20704725 | 0.84 | GSR (0.50) | DDAH1GSROTCARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12460317-B2 | Genetically encoded, phage-displayed cyclic peptide library and methods of making the same | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-11-04 | — | — | US | claimed |
| EP-4010382-B1 | POLYMER LATEX COMPOSITION FOR THE PREPARATION OF AN ELASTOMERIC FILM HAVING SELF-HEALING PROPERTIES | SYNTHOMER SDN BHD (MY) | 2024-03-20 | — | — | EP | claimed |
| US-20230139680-A1 | A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-05-04 | — | — | US | claimed |
| CN-115702004-A | Pegylated T cell adaptor with dual specificity for CD3 and CD19 | 深圳康源久远生物技术有限公司 | 2023-02-14 | — | — | CN | claimed |
| CN-115698083-A | Long-acting bispecific T cell engagers targeting CD3 and CD47 | 深圳康源久远生物技术有限公司 | 2023-02-03 | — | — | CN | claimed |
| EP-4045573-A1 | METHOD FOR THE PRODUCTION OF A CONTINUOUS ELASTOMERIC FILM | Synthomer Sdn. Bhd. (MY) | 2022-08-24 | — | — | EP | claimed |
| EP-4010382-A1 | POLYMER LATEX COMPOSITION FOR THE PREPARATION OF AN ELASTOMERIC FILM HAVING SELF-HEALING PROPERTIES | Synthomer Sdn. Bhd. (MY) | 2022-06-15 | — | — | EP | claimed |
| CN-114555680-A | Method for producing elastomeric films | 昕特玛私人有限公司 | 2022-05-27 | — | — | CN | claimed |
| EP-3972625-A1 | A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME | The Texas A&M University System (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114206950-A | Polymer latex composition for preparing elastomer film with self-repairing property | 昕特玛私人有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-113784728-A | Bispecific T cell engagers with cleavable cytokines for targeted immunotherapy | 深圳康源久远生物技术有限公司 | 2021-12-10 | — | — | CN | claimed |
| EP-0225503-B1 | RESOLUTION SYSTEM | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-08-02 | — | — | EP | claimed |
| US-20260055182-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS BIOPHARMA AG (CH) | 2026-02-26 | — | — | US | disclosed |
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-4269462-B1 | TWO COMPONENT (2K) ACRYLIC COMPOSITION COMPRISING A THERMOPLASTIC POLYURETHANE | HENKEL AG & CO KGAA (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12460317-B2 | Genetically encoded, phage-displayed cyclic peptide library and methods of making the same | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-11-04 | — | — | US | disclosed |
| US-20020041856-A1 | Use of an organometallic compound to protect and/or strengthen a keratin material, and treatment process | JEANNE-ROSE VALERIE (FR) | 2002-04-11 | — | — | US | disclosed |
| US-4864031-A | Process for the resolution of D,L-racemic mixtures | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1989-09-05 | — | — | US | disclosed |
| EP-0225503-B1 | RESOLUTION SYSTEM | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-08-02 | — | — | EP | disclosed |
| EP-0225503-A1 | Resolution system | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | ZDHHC20 3427/4885ZDHHC2 1141/4885DDAH1 82/4885 |
| US-20230139680-A1 | A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME | QPCTL, LNPEP, QPCT | ZDHHC20 899/4885ZDHHC2 2005/4885DDAH1 1509/4885 |
| US-20260055182-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IGSF11, L1CAM, CD74 | ZDHHC20 3244/4885ZDHHC2 2638/4885DDAH1 654/4885 |
| US-20020041856-A1 | Use of an organometallic compound to protect and/or strengthen a keratin material, and treatment process | KRT18, VIM, CDH1 | ZDHHC20 3453/4885ZDHHC2 3196/4885DDAH1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.